Angioedema Treatment Market 2020: focuses on companies, opportunities, market size, growth

1. Angioedema Treatment Market 2020: focuses on Angioedema Treatment Market 2020: focuses on companies, opportunities, market size, growth companies, opportunities, market size, growth Angioedema is the medical condition characterized by swelling of the lower layer of skin and tissue just under the skin or mucous membrane occurs. There are four main type of angioedema namely allergic angioedema, drug-induced angioedema, Idiopathic angioedema, and hereditary angioedema (HAE). Angioedema is caused by various factors and in most of the cases exact cause is unknown. Major cause of angioedema are allergic reaction, adverse effect of any medication, genetic defects, and infections. Request For Sample Report: Request For Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/1371 https://www.coherentmarketinsights.com/insight/request-sample/1371 Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global Frequent approval of novel drugs from regulatory bodies is expected to boost growth of global angioedema treatment market angioedema treatment market In 2017, U.S. Food and Drug Administration approved Haegarda, a C1 Esterase Inhibitor (Human) for subcutaneous administration indicated for the preventing hereditary angioedema (HAE) in adult and adolescent patients. . In 2014, Pharming Group NV and Salix Pharmaceuticals, Ltd. received US Food and Drug Administration (FDA) approval for RUCONEST (C1 Esterase Inhibitor [Recombinant]) 50 IU/kg, indicated for the treatment of acute angioedema attacks in adult and adolescent patients with HAE. In 2016, CSL Behring received FDA approval for Berinert [C1 Esterase Inhibitor (Human)], indicated for the treatment of HAE attacks in pediatric patients. These multiple approvals of new drugs by regulatory bodies are expected to drive growth of global angioedema treatment market over the forecast period. Furthermore, initiatives taken by various organizations to support treatment of angioedema is also expected to support the growth of global angioedema treatment market. For instance in 2015, British Society for Allergy and Clinical Immunology (BSACI) provided a guideline for the management of chronic urticaria and angioedema. In 2013, the World Allergy Organization (WAO) also provided guideline for the Management of Hereditary Angioedema. Angioedema Treatment Market Taxonomy Angioedema Treatment Market Taxonomy

2. The angioedema treatment market is segmented on the basis of condition type, drug type, route of administration, distribution channel, and geography By Condition Type: Allergic angioedema Drug-induced angioedema Idiopathic angioedema Hereditary angioedema (HAE) • • • • By Drug Type: C1 esterase inhibitor Cinryze Berinert Ruconest Haegarda Selective bradykinin B2 receptor antagonist Firazyr Kallikrein inhibitor Kalbitor Others • • • • • • • • • • By Route of Administration: Injection • Intravenous Subcutaneous • • Oral • By Distribution Channel Hospitals Retail pharmacies Online pharmacies • • Report includes chapters which deeply display the following deliverable about industry : Report includes chapters which deeply display the following deliverable about industry : • Angioedema Treatment Market Research Objective and Assumption • Angioedema Treatment Market Purview - Report Description, Executive Summary, and Coherent Opportunity Map (COM)

3. • Angioedema Treatment Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain Analysis, Porter’s Analysis, and PEST Analysis • Global Angioedema Treatment Market, By Regions • Angioedema Treatment Market Competition by Manufacturers including Production, Share, Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type. • Angioedema Treatment Market Manufacturers Profiles/Analysis including Company Basic Information, Manufacturing Base and Its Competitors. • Angioedema Treatment Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers of Raw Materials. • Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials Sourcing and Downstream Buyers • Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market Positioning and Distributors/Traders List. • Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer Preference Change and Economic/Political Environmental Change. • Angioedema Treatment Market Forecast including Production, Consumption, Import and Export Forecast by Type, Applications and Region. • Research Findings and Conclusion To Get Instant Access, Purchase Report Here @ To Get Instant Access, Purchase Report Here @ https://www.coherentmarketinsights.com/insight/buy- https://www.coherentmarketinsights.com/insight/buy- now/1371 now/1371 Europe angioedema treatment market is expected show significant growth, owing to increasing presence Europe angioedema treatment market is expected show significant growth, owing to increasing presence of angioedema drug manufacturers of angioedema drug manufacturers Europe is expected to be the second largest market for global angioedema treatment and it is also projected to witness a significant growth over the forecast period, owing to increasing number of new manufacturing plant in region. For instance in January 2018, Shire plc received U.S. Food and Drug Administration approval for the technology transfer of CINRYZE  (C1 esterase inhibitor [human]) drug product manufacturing process to Vienna, Austria manufacturing site. CINRYZE is an injectable prescription medicine indicated for the treatment of HAE in teenagers and adults. North America is expected to hold the dominant position in global angioedema treatment market due to approval of new drugs indicated for the treatment of angioedema. For instance in 2014, Shire Canada Inc. received

4. approval for its FIRAZYR (icatibant injection) in Canada. FIRAZYR is indicated for the treatment of acute attacks of HAE in adults with C1-esterase inhibitor deficiency. Key players in angioedema treatment market include Shire plc, CSL Limited, Pharming Group NV, Ionis Pharmaceuticals, Inc., iBio Inc., and BioCryst Pharmaceuticals, Inc. In 2017, Shire plc. received European Commission (EC) approval for label extension, that increases indication for FIRAZYR (icatibant injection), broadening use to adolescents and children aged 2 years and older, with HAE caused by C1- esterase-inhibitor (C1-INH) deficiency. About Coherent Market Insights About Coherent Market Insights Coherent Market Insights is a prominent market research and consulting firm offering action- ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Contact Us Contact Us Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Phone: US +12067016702 / UK +4402081334027 Email: Email: sales@coherentmarketinsights.com sales@coherentmarketinsights.com